Array BioPharma

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Company Growth (employees)
Type
Public
HQ
Boulder, US
Founded
1998
Size (employees)
209 (est)+19%
Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Cambridge, Morrisville, Houston and in 7 other locations
Boulder, US (HQ)
3200 Walnut St
Morrisville, US
115 3005 Carrington Mill Blvd
Cambridge, US
301 125 Cambridge Park Dr
Show all (11)

Array BioPharma Financials and Metrics

Array BioPharma Financials

Array BioPharma's revenue was reported to be $137.9 m in FY, 2016
USD

Revenue (Q1, 2018)

29.7 m

Net income (Q1, 2018)

(38 m)

EBIT (Q1, 2018)

(35.5 m)

Market capitalization (13-Nov-2017)

1.9 b
Array BioPharma's current market capitalization is $1.9 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

42.1 m51.9 m137.9 m

Revenue growth, %

23%166%

EBIT

(75.6 m)3.3 m(82.2 m)

EBIT margin, %

(180%)6%(60%)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

35.4 m43 m39.3 m44.5 m33.3 m29.7 m

General and administrative expense

9.9 m8.4 m7.9 m8.8 m11.7 m12 m

Operating expense total

57 m63.1 m63.3 m64.3 m65.2 m65.3 m

EBIT

(21.5 m)(20 m)(24 m)(19.8 m)(31.9 m)(35.5 m)
USDFY, 2014FY, 2015FY, 2016

Cash

68.6 m55.7 m56.6 m

Accounts Receivable

5.4 m6.3 m39.3 m

Inventories

5.2 m6.4 m6.1 m

Current Assets

121.7 m191 m155.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

65 m47.2 m52.2 m46.8 m68.1 m141.5 m56.4 m

Accounts Receivable

1 m5.7 m4.4 m6 m4.9 m2.1 m13.5 m

Current Assets

134.2 m128.5 m118.1 m122.8 m150.8 m196.6 m179.6 m

PP&E

9.1 m8.4 m7.8 m7.8 m8.1 m7.5 m5 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(85.3 m)9.4 m(92.8 m)

Depreciation and Amortization

4.5 m3.7 m1.5 m

Accounts Receivable

4.2 m(7.6 m)(33 m)

Cash From Operating Activities

(71.7 m)(5.8 m)(70.1 m)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(15.7 m)(32.1 m)(57 m)(27.6 m)(36.2 m)22.1 m(21 m)(24.2 m)(22.7 m)(28.6 m)(23.3 m)(35.3 m)

Depreciation and Amortization

1.1 m2.4 m3.6 m876 k1.8 m2.8 m473 k

Accounts Receivable

8.6 m3.9 m5.2 m(571 k)551 k(3.4 m)(7.2 m)64.8 m62.9 m33.9 m43.1 m32.5 m26.6 m

Accounts Payable

12.1 m15.6 m5.9 m6.5 m7.8 m8.9 m
USDY, 2017

Revenue/Employee

142.3 k
Show all financial metrics

Array BioPharma Market Value History

Array BioPharma's Web-traffic and Trends

Array BioPharma Company Life and Culture

You may also be interested in